30 Day Trial


Founded in 1992, ORTHOWORLD® is the only provider of strategic intelligence in the world solely focused on the global orthopaedic market. Its singular mission is helping orthopaedic companies and individuals improve their performance.

Highly specialized product offerings such as ORTHOWORLD Membership, ORTHOFLASH®, market reports, ORTHOPRENEUR®, BONEZONE® and OMTEC® empower industry participants to respond to challenges, maximize opportunities and more aggressively expand their orthopaedic businesses. We welcome the opportunity to assist you.


  • 12:30 p.m. Data from a 12-month study of 1-level ACDF patients treated with Trinity Evolution® + a PEEK interbody spacer demonstrated fusion rates of 78.6% at 6 months and 93.5% at one year.
  • Pluristem Therapeutics intends to conduct a U.S./EU Phase III trial assessing use of PLX-PAD (PLacental eXpanded) cells to support recovery following surgery for femoral neck fracture.
  • NuVasive reported 2Q16 revenue of US $236.2MM, +16.4% from 2Q15. (U.S. $200.5MM, +12.7%; ex-U.S. $35.6MM, +43.6%) All growth is as reported.
Read More

Articles of Interest All Articles

Recent Activities Further Progress for 2-level Cervical Disc Replacement in the U.S.

Zimmer Biomet's finalization of its $1 billion acquisition of LDR, which added Mobi-C to its spine portfolio, and Medtronic’s FDA Premarket Approval for a 2-level application for Prestige LP changes the players in the 2-level disc market.